Skip to content
Study details
Enrolling now

Anticholinergic Deprescription in Schizophrenia

Deepak K. Sarpal, M.D.
NCT IDNCT06562608ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

105

Study length

about 4.4 years

Ages

40–70

Locations

1 site in PA

What this study is about

Researchers are testing whether stopping unnecessary anticholinergic medications can improve quality of life, functioning, and thinking skills in people with schizophrenia. Participants will be randomly assigned to either continue taking their current medication or undergo a deprescribing process if deemed clinically appropriate. The trial will last for 1610 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Anticholinergic Deprescription
  • 2.Take No Anticholinergic Deprescription

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Change in scores on quality of life assessments.

Body systems

Psychiatry / Mental Health